Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women

J Clin Pharmacol. 1999 Sep;39(9):936-40. doi: 10.1177/00912709922008560.

Abstract

This study was conducted to investigate the effect of therapeutic estrogen on cytochrome P450 1A2-mediated metabolism in postmenopausal women using caffeine as a model substrate. Twelve healthy postmenopausal women underwent estrogen replacement therapy in the form of estradiol (Estrace). Estradiol was initiated at a dose of 0.5 mg a day and titrated to achieve a steady-state plasma concentration of 50 to 150 pg/ml. Caffeine metabolic ratios (CMR; paraxanthine/caffeine) were assessed both before and after 8 weeks of estrogen replacement. For the 12 subjects, there was a mean reduction in CMR of -29.2 +/- 25.0 (p = 0.0019). Consistent with previous results found in younger women, these results indicate that exogenous estrogen in older women may inhibit CYP1A2-mediated caffeine metabolism.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Caffeine / administration & dosage
  • Caffeine / blood
  • Caffeine / metabolism*
  • Central Nervous System Stimulants / administration & dosage
  • Central Nervous System Stimulants / blood
  • Central Nervous System Stimulants / metabolism
  • Chromatography, High Pressure Liquid
  • Cytochrome P-450 CYP1A2 / physiology*
  • Cytochrome P-450 CYP1A2 Inhibitors
  • Drug Interactions
  • Estradiol / administration & dosage
  • Estradiol / pharmacology*
  • Estrogen Replacement Therapy / adverse effects*
  • Female
  • Humans
  • Menopause / metabolism*
  • Middle Aged
  • Theophylline / blood*

Substances

  • Central Nervous System Stimulants
  • Cytochrome P-450 CYP1A2 Inhibitors
  • Caffeine
  • Estradiol
  • Theophylline
  • Cytochrome P-450 CYP1A2
  • 1,7-dimethylxanthine